P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC Chanchai Charonpongsuntorn,

Slides:

Advertisements

Similar presentations

P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC Jose Carlos Ruffinelli,

Advertisements

SC17.02 Lung Cancer in China: Challenges and Perspectives

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Journal of Thoracic Oncology Volume 11, Issue 4, Pages (April 2016)

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

P3.02b-001 Phase 1 Dose Escalation of PF (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC Hatim Husain,

SC09.04 Radiotherapy in China

P Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies Maria Echavarria, Anna.

Journal of Thoracic Oncology Volume 12, Issue 3, Pages (March 2017)

P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients Peter Berzinec,

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact Shaohua Lu, Takashi.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris, Meredith.

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC Rafal Dziadziuszko,

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study Franco.

Journal of Thoracic Oncology Volume 12, Issue 5, Pages (May 2017)

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Journal of Thoracic Oncology Volume 13, Issue 2, Pages (February 2018)

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

P3.02a-012 Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy You Lu,

P ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD- 1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

Journal of Thoracic Oncology Volume 11, Issue 2, Pages (February 2016)

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

Support Your Specialty

P1.22: Temporal Survival Improvement for Stage-II (T3N0M0) Lung Adenocarcinoma After Pulmonary Lobectomy Danny T. Nguyen, Jacques-Pierre Fontaine, Lary.

Journal of Thoracic Oncology Volume 12, Issue 7, Pages (July 2017)

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

Erratum The American Journal of Human Genetics

Journal of Thoracic Oncology Volume 12, Issue 8, Pages (August 2017)

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

Journal of Thoracic Oncology Volume 11, Issue 10, Pages (October 2016)

Journal of Thoracic Oncology Volume 12, Issue 10, Pages (October 2017)

P Comparison of Pulmonary Function after Robotic-Assisted Video- Thoracoscopic Lobectomies vs Segmentectomies Maria Echavarria, Anna Cheng, Frank.

Journal of Thoracic Oncology Volume 11, Issue 5, Pages (May 2016)

Journal of Thoracic Oncology Volume 11, Issue 8, Pages (August 2016)

Journal of Thoracic Oncology

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Sarah Goldberg, James.

MINI01.11: Radiotherapy Plus EGFR TKIs for Brain Metastasis in EGFR-Mutant Non– Small Cell Lung Cancer: A Retrospective Analysis of a Single Institution

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

OA07.06 In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces Takashi Eguchi, Koji.

In This Issue Journal of Thoracic Oncology

Table of Contents Journal of Thoracic Oncology

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Journal of Thoracic Oncology Volume 13, Issue 3, Pages (March 2018)

P Clinical Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Thymic Epithelial Tumor Undergoing Surgery S. Okada, S.

European Lung Cancer Conference (ELCC) 2016 Organisation

P Implications of 8th Edition TNM Proposal: Invasive vs

OA Video-Assisted Thoracoscopic Surgery vs

MA02.10 The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System H. Hamann, S. Lee, T. Browning, C. Chavez,

PUB001 Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng.

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

Journal of Thoracic Oncology Volume 13, Issue 6, Pages (June 2018)

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

The Journal of Thoracic and Cardiovascular Surgery

Journal of Thoracic Oncology

PS01.37: Comparison Between Sanger Sequencing and ARMS qPCR Method for EGFR Gene Mutation Detection of Non–Small Cell Lung Cancer Jiexia Zhang, Xiaoshun.

P1. 02: Lung Cancer - A Previously Years Survival Study

PUB019 Preoperative Needle Biopsy and Tumor Spread through Alveolar Spaces (STAS) in Resected Lung Adenocarcinomas Koji Kameda, Takashi Eguchi, Shaohua.

Y. Lou, R. Manochakian, J. Cochuyt, D. Hodge, S. Ailawadhi

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC Chanchai Charonpongsuntorn, Pimpin Incharoen, Narumol Trachu, Dittapol Muntham, Kaettipong Kampreasart, Sakdiat Saowapa, Ekaphop Sirichainan, Thanyanan Reungwetwattana Journal of Thoracic Oncology Volume 12, Issue 1, (January 2017) DOI: 10.1016/j.jtho.2016.11.1684 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, DOI: (10. 1016/j. jtho. 2016. 11 Copyright © 2016 Terms and Conditions